跳至主要内容
临床试验/NCT05689229
NCT05689229已完成3 期

Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial

Beni-Suef University1 个研究点 分布在 1 个国家目标入组 128 人开始时间: 2021年8月3日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
128
试验地点
1
主要终点
Microbial eradication

研究概览

简要总结

Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Covid-19 patients with secondary gram-negative bacterial infections

排除标准

  • Patients with resistant bacterial strains to polymyxins
  • patients less than 18 years

研究组 & 干预措施

Colistin IV

Active Comparator

干预措施: Colistin (Drug)

Colistin Aerosolized

Active Comparator

干预措施: Colistin (Drug)

结局指标

主要结局

Microbial eradication

时间窗: 10 days

Mortality

时间窗: 30 days

次要结局

  • Nephrotoxicity(10 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hasnaa Osama

Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University

Beni-Suef University

研究点 (1)

Loading locations...

相似试验